Reduction in hepatic endothelin-1 clearance in cirrhosis
Circulating endothelin-1 (ET-1) levels are increased in cirrhosis. The liver is an important site for circulating ET-1 clearance through the ET(B) receptor. We evaluated ET-1 kinetics in cirrhosis to determine if a reduced liver clearance contributes to this process. Cirrhosis was induced by carbon...
Uložené v:
| Vydané v: | Clinical science (1979) Ročník 105; číslo 2; s. 227 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
01.08.2003
|
| Predmet: | |
| ISSN: | 0143-5221 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Circulating endothelin-1 (ET-1) levels are increased in cirrhosis. The liver is an important site for circulating ET-1 clearance through the ET(B) receptor. We evaluated ET-1 kinetics in cirrhosis to determine if a reduced liver clearance contributes to this process. Cirrhosis was induced by carbon tetrachloride in rats. Hepatic ET-1 clearance was measured in isolated perfused livers using the single bolus multiple indicator-dilution technique. Plasma ET-1 levels doubled in cirrhosis from 0.49+/-0.04 fmol/ml (mean+/-S.E.M.) to 1.0+/-0.18 fmol/ml ( P <0.01). Liver ET-1 extraction was reduced from 81+/-1% (mean+/-S.E.M.) in controls to 50+/-6% in cirrhosis ( P <0.01). Kinetic modelling revealed a major irreversible binding site for ET-1 that is blocked by the selective ET(B) receptor antagonist BQ788 and a minor non-specific reversible binding site that cannot be blocked with BQ788 or the selective ET(A) antagonist BQ123. Reduced hepatic clearance correlated with the biochemical markers of cirrhosis, portal vein perfusion pressure ( r =-0.457; P <0.001) and the increase in ET-1 levels ( r =-0.462; P =0.002). Immunohistofluorescence with specific anti-(ET(B) receptor) antibodies revealed a preponderant distribution of ET(B) receptors on hepatic stellate cells, which was increased in cirrhosis. We conclude that cirrhosis reduces ET-1 clearance probably by capillarization of hepatic sinusoids and reduced access to ET(B) receptors. This relates to the severity of cirrhosis and may contribute to the increase in circulating ET-1 levels. |
|---|---|
| AbstractList | Circulating endothelin-1 (ET-1) levels are increased in cirrhosis. The liver is an important site for circulating ET-1 clearance through the ET(B) receptor. We evaluated ET-1 kinetics in cirrhosis to determine if a reduced liver clearance contributes to this process. Cirrhosis was induced by carbon tetrachloride in rats. Hepatic ET-1 clearance was measured in isolated perfused livers using the single bolus multiple indicator-dilution technique. Plasma ET-1 levels doubled in cirrhosis from 0.49+/-0.04 fmol/ml (mean+/-S.E.M.) to 1.0+/-0.18 fmol/ml ( P <0.01). Liver ET-1 extraction was reduced from 81+/-1% (mean+/-S.E.M.) in controls to 50+/-6% in cirrhosis ( P <0.01). Kinetic modelling revealed a major irreversible binding site for ET-1 that is blocked by the selective ET(B) receptor antagonist BQ788 and a minor non-specific reversible binding site that cannot be blocked with BQ788 or the selective ET(A) antagonist BQ123. Reduced hepatic clearance correlated with the biochemical markers of cirrhosis, portal vein perfusion pressure ( r =-0.457; P <0.001) and the increase in ET-1 levels ( r =-0.462; P =0.002). Immunohistofluorescence with specific anti-(ET(B) receptor) antibodies revealed a preponderant distribution of ET(B) receptors on hepatic stellate cells, which was increased in cirrhosis. We conclude that cirrhosis reduces ET-1 clearance probably by capillarization of hepatic sinusoids and reduced access to ET(B) receptors. This relates to the severity of cirrhosis and may contribute to the increase in circulating ET-1 levels. Circulating endothelin-1 (ET-1) levels are increased in cirrhosis. The liver is an important site for circulating ET-1 clearance through the ET(B) receptor. We evaluated ET-1 kinetics in cirrhosis to determine if a reduced liver clearance contributes to this process. Cirrhosis was induced by carbon tetrachloride in rats. Hepatic ET-1 clearance was measured in isolated perfused livers using the single bolus multiple indicator-dilution technique. Plasma ET-1 levels doubled in cirrhosis from 0.49+/-0.04 fmol/ml (mean+/-S.E.M.) to 1.0+/-0.18 fmol/ml ( P <0.01). Liver ET-1 extraction was reduced from 81+/-1% (mean+/-S.E.M.) in controls to 50+/-6% in cirrhosis ( P <0.01). Kinetic modelling revealed a major irreversible binding site for ET-1 that is blocked by the selective ET(B) receptor antagonist BQ788 and a minor non-specific reversible binding site that cannot be blocked with BQ788 or the selective ET(A) antagonist BQ123. Reduced hepatic clearance correlated with the biochemical markers of cirrhosis, portal vein perfusion pressure ( r =-0.457; P <0.001) and the increase in ET-1 levels ( r =-0.462; P =0.002). Immunohistofluorescence with specific anti-(ET(B) receptor) antibodies revealed a preponderant distribution of ET(B) receptors on hepatic stellate cells, which was increased in cirrhosis. We conclude that cirrhosis reduces ET-1 clearance probably by capillarization of hepatic sinusoids and reduced access to ET(B) receptors. This relates to the severity of cirrhosis and may contribute to the increase in circulating ET-1 levels.Circulating endothelin-1 (ET-1) levels are increased in cirrhosis. The liver is an important site for circulating ET-1 clearance through the ET(B) receptor. We evaluated ET-1 kinetics in cirrhosis to determine if a reduced liver clearance contributes to this process. Cirrhosis was induced by carbon tetrachloride in rats. Hepatic ET-1 clearance was measured in isolated perfused livers using the single bolus multiple indicator-dilution technique. Plasma ET-1 levels doubled in cirrhosis from 0.49+/-0.04 fmol/ml (mean+/-S.E.M.) to 1.0+/-0.18 fmol/ml ( P <0.01). Liver ET-1 extraction was reduced from 81+/-1% (mean+/-S.E.M.) in controls to 50+/-6% in cirrhosis ( P <0.01). Kinetic modelling revealed a major irreversible binding site for ET-1 that is blocked by the selective ET(B) receptor antagonist BQ788 and a minor non-specific reversible binding site that cannot be blocked with BQ788 or the selective ET(A) antagonist BQ123. Reduced hepatic clearance correlated with the biochemical markers of cirrhosis, portal vein perfusion pressure ( r =-0.457; P <0.001) and the increase in ET-1 levels ( r =-0.462; P =0.002). Immunohistofluorescence with specific anti-(ET(B) receptor) antibodies revealed a preponderant distribution of ET(B) receptors on hepatic stellate cells, which was increased in cirrhosis. We conclude that cirrhosis reduces ET-1 clearance probably by capillarization of hepatic sinusoids and reduced access to ET(B) receptors. This relates to the severity of cirrhosis and may contribute to the increase in circulating ET-1 levels. |
| Author | Dupuis, Jocelyn Tran Duc, Anh Thu Simard, André Schwab, Andreas J Villeneuve, Louis |
| Author_xml | – sequence: 1 givenname: Anh Thu surname: Tran Duc fullname: Tran Duc, Anh Thu organization: Research Center, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada H1T 1C8 – sequence: 2 givenname: Andreas J surname: Schwab fullname: Schwab, Andreas J – sequence: 3 givenname: André surname: Simard fullname: Simard, André – sequence: 4 givenname: Louis surname: Villeneuve fullname: Villeneuve, Louis – sequence: 5 givenname: Jocelyn surname: Dupuis fullname: Dupuis, Jocelyn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12708965$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1j81LxDAUxHNYcT_04h8gPXmrvry0TXuUxS9YEETPJX15oZE2XZv24H9vxZU5DAw_ZpitWIUhsBBXEm4lZHhHEQEUABYrsQGZqTRHlGuxjfFzSdWic7GWqKGsinwjyje2M01-CIkPSctHM3lKONhharnzIZUJdWxGE4h_CfLj2A7Rxwtx5kwX-fLkO_Hx-PC-f04Pr08v-_tDSnIZSKlxFTSu1FIjuEoaYGsJ0IKTrNkarStCU1qDuSocKJ25qiGFhES2MrgTN3-9x3H4mjlOde8jcdeZwMMca61y0CjlAl6fwLnp2dbH0fdm_K7_v-IPGXpU1g |
| CitedBy_id | crossref_primary_10_1139_Y10_038 crossref_primary_10_1164_rccm_200403_340OC crossref_primary_10_1016_j_jhep_2005_10_034 crossref_primary_10_1002_lt_20477 crossref_primary_10_1152_physrev_00027_2008 crossref_primary_10_1016_j_surg_2005_07_006 crossref_primary_10_1080_10739680590960322 crossref_primary_10_1139_Y10_041 crossref_primary_10_1097_CRD_0b013e3181aa8f4a crossref_primary_10_1002_hep_20940 crossref_primary_10_1002_poh2_17 crossref_primary_10_1161_HYPERTENSIONAHA_107_100586 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1042/cs20030026 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 12708965 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 0VX 29B 2WC 3O- 4.4 53G 5GY 5RE 5VS 6J9 AABGO AAHRG ABCQX ABJNI ACGFO ACGFS ADBBV AEGXH AENEX AFFNX AFFVI AI. AIAGR AIZAD ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CS3 CUY CVF DU5 E3Z EBD EBS ECM EIF EJD EMOBN F5P GX1 H13 HZ~ L7B MV1 MVM NPM NTEUP O9- OHT P2P P6G RHI RPO SV3 TR2 VH1 WH7 X7M ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c1965-cbf90bf871720f91a0eddc02d0f1e7eda779c2a8da2536f0374f9bc32c2ccd9a2 |
| IEDL.DBID | 7X8 |
| ISSN | 0143-5221 |
| IngestDate | Fri Jul 11 16:05:28 EDT 2025 Sat Sep 28 07:47:32 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1965-cbf90bf871720f91a0eddc02d0f1e7eda779c2a8da2536f0374f9bc32c2ccd9a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 12708965 |
| PQID | 73507211 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_73507211 pubmed_primary_12708965 |
| PublicationCentury | 2000 |
| PublicationDate | 2003-Aug 20030801 |
| PublicationDateYYYYMMDD | 2003-08-01 |
| PublicationDate_xml | – month: 08 year: 2003 text: 2003-Aug |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Clinical science (1979) |
| PublicationTitleAlternate | Clin Sci (Lond) |
| PublicationYear | 2003 |
| SSID | ssj0023232 |
| Score | 1.6784008 |
| Snippet | Circulating endothelin-1 (ET-1) levels are increased in cirrhosis. The liver is an important site for circulating ET-1 clearance through the ET(B) receptor. We... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 227 |
| SubjectTerms | Animals Blood Pressure Carbon Tetrachloride Endothelin-1 - blood Endothelin-1 - metabolism Liver - metabolism Liver Cirrhosis, Experimental - blood Liver Cirrhosis, Experimental - metabolism Liver Cirrhosis, Experimental - pathology Male Portal Vein - physiopathology Rats Rats, Sprague-Dawley Receptor, Endothelin B Receptors, Endothelin - metabolism |
| Title | Reduction in hepatic endothelin-1 clearance in cirrhosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/12708965 https://www.proquest.com/docview/73507211 |
| Volume | 105 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELYKRYiF96M8M7BaTRy3tiUkhCoqllYVD6lb5JxtNUtSGuD343MTNsTAkimRrPPFucv33fcRcqvF0GkJmqK2N-XgBNUpH1CZO5cmBlRsZTCbENOpnM_VrEPu2lkYpFW2Z2I4qE0F-I-8L9IBSnkl98t3ip5RiK02BhobpJv6QgZzWsx_MARfKgR7MhSw8-0WS1pxUs76oxfkZMVBUuG3wjJ8YMZ7_1vaPtltCsvoYZ0JB6Rjy0OyPWmg8yMin1GkFbchKspoYZFJDZEtDY5g-VqTJhGghQRmAd4BxWq1qOqiPiZv48fX0RNtbBMooDwghdypOHe-ExIsdirRsTUGYmZil1hhjRZCAdPSaDZIhw4FaJzKIWXAAIzS7IRsllVpz0gEODnLrPQ9R865MxKc5dJwn34qzbnrkZs2IplPS8QadGmrzzprY9Ijp-ugZsu1ekaGULf06zz_89kLshOoc4Fud0m6zr-Q9opswddHUa-uw27763Q2-QaSurUJ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+in+hepatic+endothelin-1+clearance+in+cirrhosis&rft.jtitle=Clinical+science+%281979%29&rft.au=Tran+Duc%2C+Anh+Thu&rft.au=Schwab%2C+Andreas+J&rft.au=Simard%2C+Andr%C3%A9&rft.au=Villeneuve%2C+Louis&rft.date=2003-08-01&rft.issn=0143-5221&rft.volume=105&rft.issue=2&rft.spage=227&rft_id=info:doi/10.1042%2Fcs20030026&rft_id=info%3Apmid%2F12708965&rft_id=info%3Apmid%2F12708965&rft.externalDocID=12708965 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0143-5221&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0143-5221&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0143-5221&client=summon |